Business Description
Amplia Therapeutics Ltd
ISIN : AU0000023822
Description
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 81.68 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.9 | |||||
3-Year EPS without NRI Growth Rate | 19.8 | |||||
3-Year FCF Growth Rate | 9.9 | |||||
3-Year Book Growth Rate | -0.4 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.22 | |||||
9-Day RSI | 61.24 | |||||
14-Day RSI | 55 | |||||
3-1 Month Momentum % | -34.78 | |||||
6-1 Month Momentum % | 20 | |||||
12-1 Month Momentum % | -23.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.79 | |||||
Quick Ratio | 19.79 | |||||
Cash Ratio | 16.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.1 | |||||
Shareholder Yield % | -44.64 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -22.36 | |||||
ROA % | -21.23 | |||||
ROIC % | -107.92 | |||||
3-Year ROIIC % | -335 | |||||
ROC (Joel Greenblatt) % | -354.21 | |||||
ROCE % | -22.17 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.74 | |||||
Price-to-Tangible-Book | 2.25 | |||||
EV-to-EBIT | -5.43 | |||||
EV-to-EBITDA | -5.5 | |||||
EV-to-FCF | -3.6 | |||||
| Price-to-Net-Current-Asset-Value | 2.25 | |||||
| Price-to-Net-Cash | 2.7 | |||||
Earnings Yield (Greenblatt) % | -18.39 | |||||
FCF Yield % | -12.66 |
GF Valueâ„¢
Amplia Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amplia Therapeutics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2018-04-30 | 0.37 (+0.00%) |
Show
Entries
Press Release
Articles on Amplia Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers